ASH 2022 | Cost-effectiveness of brexu-cel in adult patients with R/R ALL in the US
Michael Bishop, MD, University of Chicago, Chicago, IL, discusses the results of a study that compared the cost of CAR-T therapy with brexucabtagene autoleucel (brexu-cel) versus other therapies in adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Overall, the study showed that CAR-T therapy is likely to be a cost-effective treatment when considering the long-term benefits to patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Honoraria, Other: Travel support, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Travel support , Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Agios: Consultancy, Honoraria, Other: Travel support, Speakers Bureau; Iovance: Consultancy; Bluebird Bio: Consultancy; WindMIL Therapeutics: Consultancy; Arcellx: Consultancy, Research Funding; Autolus: Consultancy, Research Funding; Immatics: Research Funding; Triumvira: Research Funding; Tmunity: Research Funding; Chimeric Therapeutics: Consultancy; Sanofi: Honoraria, Speakers Bureau; Sana Biotechnology: Consultancy; Servier: Speakers Bureau; ADC Therapeutics: Speakers Bureau; Celgene: Honoraria; Incyte: Honoraria, Other: Travel support , Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel support, Research Funding, Speakers Bureau.
